A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : TOX / toxicity

[Related PubMed/MEDLINE]
Total Number of Papers: 34
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   TOX  (>> Co-occurring Abbreviation)
Long Form:   toxicity
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2- Advanced Breast Cancer in the MONALEESA-3 Trial. ABC, HR, OS, PROG, QA, QAPFS, TWiST
2021 Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study. Q-TWiST
2021 Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma. CIs, EVE, LEN, Q-TWiST, RCC
2020 A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer. BTC, CCA, DCR, LA, ORR, OS, pts, RES, TTP
2020 Ingenuity pathway analysis of human facet joint tissues: Insight into facet joint osteoarthritis. DEGs, FJOA, IPA
2020 Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance). aRCC, Q-TWiST
2019 A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator's Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck. IC, Q-TWiST, REL, TWiST
2019 A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (aRCC). aRCC, OS, Q-TWiST
2018 Analysis of hematological parameters as prognostic markers for toxicity and survival of 223Radium treatment. 223Ra, CRPC, HT
10  2018 Hematopoiesis is prognostic for toxicity and survival of 223Radium treatment in patients with metastatic castration-resistant prostate cancer. 223Ra, Hb, HT, Leuk, PLTs
11  2018 Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis. AEs, CI, nab-P, PAC, Q-TWiST, REL
12  2017 QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer. AEs, mCRC, QoL, QTWiST, REL, TWiST
13  2017 Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis. Q-TWiST
14  2016 Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma. Q-TWiST, REL
15  2015 Analysis of survival adjusted for quality of life using the Q-TWiST function: Interface in R. REL
16  2015 Q-TWiST analysis of panitumumab plus FOLFOX4 versus FOLFOX4 alone in patients with previously untreated wild-type RAS metastatic colorectal cancer. mCRC, Q-TWiST, REL, TWiST
17  2014 Comparison of accelerated hypofractionation and stereotactic body radiotherapy for Stage 1 and node negative Stage 2 non-small cell lung cancer (NSCLC). AHRT, LC, mo, NSCLC, SBRT
18  2013 Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma. CR, mRCC, OR, OS, PD, PFS, PR, SD, TT
19  2011 Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer. Cape, FACT, Q-TWiST, QAS, REL
20  2011 Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2+ metastatic breast cancer with letrozole alone or in combination with lapatinib. Let, TWiST
21  2010 Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma. IFN, Q-TWiST, RCC, TWiST
22  2009 Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial. NSCLC, Q-TWiST, REL, TWiST
23  2009 Removal of Cu(II) ions by biosorption onto powdered waste sludge (PWS) prior to biological treatment in an activated sludge unit: a statistical design approach. COD, PWS, SVI
24  2008 Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. MBC, Q-TWiST, REL, TWiST
25  2007 Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. QL, REL, SD-CT, TWiST
26  2005 Q-TWiST analysis of cyclophosphamide, epirubicin, fluorouracil versus cyclophosphamide, methotrexate, fluorouracil treatment for premenopausal women with node-positive breast cancer. CEF, CMF, DFS, OS
27  2005 Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer. PROG
28  2004 Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer. CMF, Q-TWiST, QL, REL
29  1999 Quality-adjusted survival after treatment for acute myeloid leukemia in childhood: A Q-TWiST analysis of the Pediatric Oncology Group Study 8821. ABMT, CC, Q-TWiST, TWiST
30  1998 Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma. IFN, NCIC CTG, Q-TWiST, REL, TWiST
31  1996 Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. Q-TWiST, REL
32  1996 The effects of extracellular ions on beta-blocker cardiotoxicity. ATEN, KHB, PROP
33  1991 Synthesis and anticonvulsant activity of imidooxy derivatives. MES, NINCDS
34  1989 Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. DFS, OS, REL, TWiST